Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Drug Des Devel Ther. 2020 Mar 2;14:951-959. doi: 10.2147/DDDT.S240615. eCollection 2020.
The currently approved treatment for female pattern hair loss (FPHL) includes topical minoxidil administration; however, this treatment fails to achieve hair regrowth in some patients. Finasteride, a selective 5α-reductase inhibitor (5-ARI), may be considered as an alternative treatment. However, because of its potential teratogenic effects, clinical studies and use of finasteride for FPHL are limited. In this review, we aim to summarize the literature regarding the pharmacology, clinical efficacy, and adverse effects of oral finasteride for the treatment of FPHL and to provide novel therapeutic options including topical finasteride and dutasteride, a new generation 5-ARI, for the treatment of FPHL.
目前，女性型脱发（FPHL）的治疗方法包括局部使用米诺地尔；然而，这种治疗方法并不能使一些患者的头发再生。非那雄胺，一种选择性 5α-还原酶抑制剂（5-ARI），可以被认为是一种替代治疗方法。然而，由于其潜在的致畸作用，临床研究和非那雄胺在 FPHL 中的应用受到限制。在这篇综述中，我们旨在总结关于口服非那雄胺治疗 FPHL 的药理学、临床疗效和不良反应的文献，并提供新的治疗选择，包括局部使用非那雄胺和达那唑，一种新一代 5-ARI，用于治疗 FPHL。
